CRSP vs. EXEL, NBIX, MRNA, QGEN, TECH, RGEN, HALO, RVMD, ADMA, and KRYS
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Exelixis (EXEL), Neurocrine Biosciences (NBIX), Moderna (MRNA), Qiagen (QGEN), Bio-Techne (TECH), Repligen (RGEN), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics vs.
Exelixis (NASDAQ:EXEL) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.
Exelixis has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 15 more articles in the media than Exelixis. MarketBeat recorded 55 mentions for CRISPR Therapeutics and 40 mentions for Exelixis. Exelixis' average media sentiment score of 1.44 beat CRISPR Therapeutics' score of 0.17 indicating that Exelixis is being referred to more favorably in the media.
Exelixis received 139 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 68.58% of users gave Exelixis an outperform vote while only 64.40% of users gave CRISPR Therapeutics an outperform vote.
Exelixis has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.
Exelixis currently has a consensus price target of $37.59, indicating a potential upside of 1.73%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 92.77%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Exelixis.
85.3% of Exelixis shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.8% of Exelixis shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Exelixis has a net margin of 24.04% compared to CRISPR Therapeutics' net margin of -981.54%. Exelixis' return on equity of 23.52% beat CRISPR Therapeutics' return on equity.
Summary
Exelixis beats CRISPR Therapeutics on 12 of the 18 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRSP) was last updated on 5/14/2025 by MarketBeat.com Staff
Buy CRSP Stock Free CRSP Stock Alerts